AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33785415 — intervention group
Group type: EXPERIMENTAL
Intervention: OSDI
Number of subjects: 535
Study 32862592 — intervention group
Group type: EXPERIMENTAL
Intervention: Endostatin+TAI+TACE
Number of subjects: 96
Study 32862592 — intervention group
Group type: COMPARATOR
Intervention: TAI+TACE
Number of subjects: 96
Study 36278368 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking posture
Number of subjects: 16
Study 36278368 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing posture
Number of subjects: 16
Study 36278368 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting posture
Number of subjects: 16
Study 34181597 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital animation
Number of subjects: 36
Study 34181597 — intervention group
Group type: COMPARATOR
Intervention: Text resources
Number of subjects: 36
Study 34181597 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study 32484914 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 plus best supportive care (BSC)
Number of subjects: 131
Study 32484914 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC) alone
Number of subjects: 131
Study 35645222 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional rapid-acting insulin administered at +0h
Number of subjects: 27
Study 35645222 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional rapid-acting insulin administered at +1h
Number of subjects: 27
Study 35645222 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional rapid-acting insulin administered at +2h
Number of subjects: 27
Study 35645222 — intervention group
Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 27
Study 33692190 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart agent (SA) system
Number of subjects: 20
Study 34611745 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality rehabilitation
Number of subjects: 60
Study 34611745 — intervention group
Group type: COMPARATOR
Intervention: Optokinetic stimulation rehabilitation
Number of subjects: 60
Study 33081502 — intervention group
Group type: EXPERIMENTAL
Intervention: Flash glucose monitoring
Number of subjects: 150
Study 33081502 — intervention group
Group type: COMPARATOR
Intervention: Traditional self-monitoring of blood glucose (control)
Number of subjects: 150
Study 35180646 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 6
Study 35180646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 33781141 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS‐986020 600 mg once daily (QD)
Number of subjects: 142
Study 33781141 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS‐986020 600 mg twice daily (BID)
Number of subjects: 142
Study 33781141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 32106642 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized heparin (25,000 IU) and salbutamol (5 mg) every 6 hours
Number of subjects: 60
Study 32106642 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol only (5 mg)
Number of subjects: 60
Study 36471692 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam tosylate plus low-dose propofol (Group RP)
Number of subjects: 193
Study 36471692 — intervention group
Group type: COMPARATOR
Intervention: Propofol (Group P)
Number of subjects: 193
Study 36471692 — intervention group
Group type: COMPARATOR
Intervention: Remimazolam tosylate (Group R)
Number of subjects: 193
Study 33757813 — intervention group
Group type: EXPERIMENTAL
Intervention: TST + HIIT
Number of subjects: 35
Study 33757813 — intervention group
Group type: EXPERIMENTAL
Intervention: PT + HIIT
Number of subjects: 35
Study 34916266 — intervention group
Group type: COMPARATOR
Intervention: Low-dose dexamethasone (6 mg once daily for 10 days)
Number of subjects: 200
Study 34916266 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone (20 mg once daily for 5 days, followed by 10 mg once daily for an additional 5 days)
Number of subjects: 200
Study 34916266 — intervention group
Group type: COMPARATOR
Intervention: Low-dose dexamethasone
Number of subjects: 200
Study 34916266 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone
Number of subjects: 200
Study 32019723 — intervention group
Group type: EXPERIMENTAL
Intervention: MLR-1023 100-mg once-daily (qd)
Number of subjects: 0
Study 32019723 — intervention group
Group type: EXPERIMENTAL
Intervention: MLR-1023 100-mg twice-daily (bid)
Number of subjects: 0
Study 32019723 — intervention group
Group type: EXPERIMENTAL
Intervention: MLR-1023 200-mg once-daily (qd)
Number of subjects: 0
Study 32019723 — intervention group
Group type: EXPERIMENTAL
Intervention: MLR-1023 200-mg twice-daily (bid)
Number of subjects: 0
Study 32019723 — intervention group
Group type: EXPERIMENTAL
Intervention: MLR-1023
Number of subjects: 0
Study 34062986 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum PS128 probiotic (6 × 10^10 CFUs) + Oxytocin
Number of subjects: 35
Study 34062986 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Oxytocin
Number of subjects: 35
Study 36087806 — intervention group
Group type: EXPERIMENTAL
Intervention: PUSH (specific multi-component intervention)
Number of subjects: 34
Study 36087806 — intervention group
Group type: COMPARATOR
Intervention: PULSE (active control, non-specific multi-component intervention)
Number of subjects: 34
Study 32847638 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of ultra-processed foods four times or more a day
Number of subjects: 309
Study 32931400 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 0.14 mg/kg/day (maximum 10 mg) during chemotherapy and 3 days postchemotherapy
Number of subjects: 240
Study 32931400 — intervention group
Group type: COMPARATOR
Intervention: Control group (received aprepitant, ondansetron, and dexamethasone only)
Number of subjects: 240
Study 34838987 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal nonopioid pain regimen
Number of subjects: 40
Study 34838987 — intervention group
Group type: COMPARATOR
Intervention: Standard of care narcotics (opioids)
Number of subjects: 40
Study 33464688 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (Db)
Number of subjects: 28
Study 33464688 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 28
Study 33464688 — intervention group
Group type: COMPARATOR
Intervention: Normal flow group
Number of subjects: 28
Study 36064571 — intervention group
Group type: EXPERIMENTAL
Intervention: nnU-Net (3D-Cascade U-Net)
Number of subjects: 237
Study 34582449 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-only delivery model with 16 fortnightly sessions
Number of subjects: 1152
Study 34582449 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-delivery model combining 12 group sessions with 4 home visits
Number of subjects: 1152
Study 34582449 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1152
Study 35921688 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (12-week duration)
Number of subjects: 0
Study 32295808 — intervention group
Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 321
Study 32295808 — intervention group
Group type: COMPARATOR
Intervention: Lixi
Number of subjects: 321
Study 34953748 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 255
Study 34953748 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 255
Study 32768792 — intervention group
Group type: EXPERIMENTAL
Intervention: Browsing a social networking site (SNS)
Number of subjects: 139
Study 32768792 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing brief movie clips to induce positive, negative, or neutral mood
Number of subjects: 139
Study 32768792 — intervention group
Group type: COMPARATOR
Intervention: Control website browsing
Number of subjects: 139
Study 35170013 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping at 120 seconds
Number of subjects: 68
Study 35170013 — intervention group
Group type: COMPARATOR
Intervention: Delayed cord clamping at 30 seconds
Number of subjects: 68
Study 33508499 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS treatment (5-Hz) for 2 weeks
Number of subjects: 44
Study 33508499 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS treatment (5-Hz) for 6 months (open-label maintenance phase)
Number of subjects: 44
Study 33508499 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment for 2 weeks
Number of subjects: 44
Study 35954397 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention clinic (low-SES)
Number of subjects: 0
Study 35954397 — intervention group
Group type: COMPARATOR
Intervention: Middle-SES comparison clinics
Number of subjects: 0
Study 35954397 — intervention group
Group type: COMPARATOR
Intervention: National level (low-SES)
Number of subjects: 0
Study 35640080 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic forces applied to test MSPs
Number of subjects: 32
Study 35640080 — intervention group
Group type: COMPARATOR
Intervention: Control MSPs (no orthodontic forces applied initially)
Number of subjects: 32
Study 36153583 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (n=27)
Number of subjects: 60
Study 36153583 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=33)
Number of subjects: 60
Study 36153583 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 60
Study 36153583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 32729970 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-based information and coaching/support program
Number of subjects: 67
Study 32729970 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 67
Study 32732774 — intervention group
Group type: EXPERIMENTAL
Intervention: Always superior partner
Number of subjects: 41
Study 32732774 — intervention group
Group type: COMPARATOR
Intervention: Control (no partner)
Number of subjects: 41
Study 35638203 — intervention group
Group type: EXPERIMENTAL
Intervention: Three PRP injections
Number of subjects: 102
Study 35638203 — intervention group
Group type: EXPERIMENTAL
Intervention: One PRP injection followed by two placebo injections
Number of subjects: 102
Study 35638203 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections (Normal Saline)
Number of subjects: 102
Study 35638203 — intervention group
Group type: EXPERIMENTAL
Intervention: Single or multiple PRP injections
Number of subjects: 102
Study 35638203 — intervention group
Group type: EXPERIMENTAL
Intervention: Single PRP injection
Number of subjects: 102
Study 35638203 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple PRP injections
Number of subjects: 102
Study 32856285 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sildenafil (0.5 mg/kg every 6 hours to a target maintenance dose of 2 mg/kg every 6 hours)
Number of subjects: 60
Study 32856285 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous milrinone (0.5 μg/kg/min as a continuous infusion)
Number of subjects: 60
Study 32856285 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sildenafil and intravenous milrinone (dual therapy)
Number of subjects: 60
Study 33242345 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleanliness prime
Number of subjects: 0
Study 33242345 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational presentation (Harm Reduction)
Number of subjects: 0
Study 33242345 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational presentation (Healthy Living)
Number of subjects: 0
Study 34334715 — intervention group
Group type: EXPERIMENTAL
Intervention: PAI e‐Health Program
Number of subjects: 30
Study 34334715 — intervention group
Group type: COMPARATOR
Intervention: PA attention control
Number of subjects: 30
Study 35360742 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Acupoint Stimulation (TEAS)
Number of subjects: 1655
Study 35360742 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of TEAS and palonosetron
Number of subjects: 1655
Study 35360742 — intervention group
Group type: COMPARATOR
Intervention: Sham group (control)
Number of subjects: 1655
Study 33420959 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 22
Study 33420959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 35164840 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexamethasone
Number of subjects: 120
Study 35164840 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dexamethasone
Number of subjects: 120
Study 35164840 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intranasal and intravenous dexamethasone)
Number of subjects: 120
Study 33381795 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean oil (SBO)
Number of subjects: 83
Study 33381795 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa butter (COB)
Number of subjects: 83
Study 33381795 — intervention group
Group type: COMPARATOR
Intervention: Palm olein (POo)
Number of subjects: 83
Study 34482412 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilator-piloted Pulmonary Recruitment Maneuver (PRM)
Number of subjects: 147
Study 34482412 — intervention group
Group type: COMPARATOR
Intervention: Ordinary exsufflation (Control)
Number of subjects: 147
Study 32366244 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide autogel 60/90/120 mg (monthly deep subcutaneous injection)
Number of subjects: 128
Study 32366244 — intervention group
Group type: COMPARATOR
Intervention: Lanreotide 40 mg PR (intramuscular injection every 7, 10, or 14 days)
Number of subjects: 128
Study 32366244 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide autogel
Number of subjects: 128
Study 32366244 — intervention group
Group type: COMPARATOR
Intervention: Lanreotide 40 mg PR
Number of subjects: 128
Study 36445529 — intervention group
Group type: EXPERIMENTAL
Intervention: Arabic with high certainty (very-modifier and all-quantifier)
Number of subjects: 368
Study 36445529 — intervention group
Group type: EXPERIMENTAL
Intervention: Arabic with low certainty (no very-modifier and some-quantifier)
Number of subjects: 368
Study 36445529 — intervention group
Group type: EXPERIMENTAL
Intervention: English with high certainty
Number of subjects: 368
Study 36445529 — intervention group
Group type: EXPERIMENTAL
Intervention: English with low certainty
Number of subjects: 368
Study 32452085 — intervention group
Group type: EXPERIMENTAL
Intervention: Patiromer (8.4 g once daily)
Number of subjects: 295
Study 32452085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 295
Study 36161759 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative BMI exposure (assessed using a quadratic mixed-effects method)
Number of subjects: 19477
Study 36161759 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain (BMI change: >3%) in baseline BMI <24 kg/m2
Number of subjects: 19477
Study 36161759 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (BMI change: <−3%) in baseline BMI ≥24 kg/m2
Number of subjects: 19477
Study 36161759 — intervention group
Group type: COMPARATOR
Intervention: Stable weight (BMI change: −3% to 3%)
Number of subjects: 19477
Study 34159412 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural anesthesia (CSEA) in left lateral position (Group I)
Number of subjects: 100
Study 34159412 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural anesthesia (CSEA) in sitting position (Group II)
Number of subjects: 100
Study 34159412 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group I)
Number of subjects: 100
Study 34159412 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group II)
Number of subjects: 100
Study 35914346 — intervention group
Group type: EXPERIMENTAL
Intervention: Active learning
Number of subjects: 99
Study 35914346 — intervention group
Group type: COMPARATOR
Intervention: Formal lectures
Number of subjects: 99
Study 35914346 — intervention group
Group type: EXPERIMENTAL
Intervention: Active learning and Formal lectures
Number of subjects: 99
Study 34428179 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated laser resurfacing (FLR) treatment on one lower arm
Number of subjects: 48
Study 34428179 — intervention group
Group type: COMPARATOR
Intervention: Untreated arm (control)
Number of subjects: 48
Study 33291645 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention
Number of subjects: 1773
Study 33291645 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1773
Study 35765946 — intervention group
Group type: EXPERIMENTAL
Intervention: HBeAg negative chronic HBV infection patients
Number of subjects: 132
Study 35765946 — intervention group
Group type: COMPARATOR
Intervention: Control group (308 HBsAg negative individuals)
Number of subjects: 132
Study 35765946 — intervention group
Group type: EXPERIMENTAL
Intervention: TyG index and TG/HDL‐C ratio
Number of subjects: 132
Study 32796016 — intervention group
Group type: EXPERIMENTAL
Intervention: Spraino
Number of subjects: 510
Study 32796016 — intervention group
Group type: COMPARATOR
Intervention: do-as-usual
Number of subjects: 510
Study 34090707 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use post-diagnosis
Number of subjects: 4207
Study 34090707 — intervention group
Group type: EXPERIMENTAL
Intervention: New statin use post-diagnosis
Number of subjects: 4207
Study 34090707 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued statin use from before diagnosis
Number of subjects: 4207
Study 34090707 — intervention group
Group type: COMPARATOR
Intervention: β-blocker use
Number of subjects: 4207
Study 33905494 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral doxycycline 200 mg twice daily for 10 days and prednisolone 60 mg once daily for 5 days, then tapered over 5 days
Number of subjects: 57
Study 33905494 — intervention group
Group type: COMPARATOR
Intervention: Oral doxycycline (historical control)
Number of subjects: 57
Study 33905494 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups underwent follow-up lumbar puncture and were followed until complete recovery or for 12 months
Number of subjects: 57
Study 32348882 — intervention group
Group type: EXPERIMENTAL
Intervention: Orodispersible film (ODF) 2 x 3 cm
Number of subjects: 150
Study 32348882 — intervention group
Group type: COMPARATOR
Intervention: Glucose syrup (0.5-3 mL)
Number of subjects: 150
Study 32348882 — intervention group
Group type: EXPERIMENTAL
Intervention: Orodispersible film (ODF)
Number of subjects: 150
Study 32348882 — intervention group
Group type: COMPARATOR
Intervention: Glucose syrup
Number of subjects: 150
Study 35086141 — intervention group
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin and bendamustine plus rituximab (BR)
Number of subjects: 33
Study 35086141 — intervention group
Group type: COMPARATOR
Intervention: BR alone
Number of subjects: 33
Study 35086141 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete response (CR) group (n = 13)
Number of subjects: 33
Study 35086141 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-complete response (non-CR) group (n = 10)
Number of subjects: 33
Study 33190420 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot reflexology
Number of subjects: 47
Study 33190420 — intervention group
Group type: COMPARATOR
Intervention: Control group (resting)
Number of subjects: 47
Study 35897086 — intervention group
Group type: EXPERIMENTAL
Intervention: iCanCope with PainTM app
Number of subjects: 73
Study 35897086 — intervention group
Group type: COMPARATOR
Intervention: Symptom tracking app (control)
Number of subjects: 73
Study 34862813 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained nurse home visiting intervention
Number of subjects: 352
Study 33346444 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 27
Study 33346444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 35986615 — intervention group
Group type: EXPERIMENTAL
Intervention: Assar's technique
Number of subjects: 0
Study 35986615 — intervention group
Group type: EXPERIMENTAL
Intervention: Shehata's technique
Number of subjects: 0
Study 34342017 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline supplementation
Number of subjects: 52
Study 34342017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 32176166 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma Quality of Life Clinic (TQOL)
Number of subjects: 36
Study 32176166 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 36
Study 33269530 — intervention group
Group type: EXPERIMENTAL
Intervention: semaglutide 2.4 mg
Number of subjects: 72
Study 33260064 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir-Ritonavir (Group A)
Number of subjects: 60
Study 33260064 — intervention group
Group type: COMPARATOR
Intervention: Huashi Baidu Formula + Lopinavir-Ritonavir (Group B)
Number of subjects: 60
Study 33260064 — intervention group
Group type: EXPERIMENTAL
Intervention: Huashi Baidu Formula (Group C)
Number of subjects: 60
Study 33058158 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 11590
Study 33058158 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 11590
Study 36398729 — intervention group
Group type: EXPERIMENTAL
Intervention: Single balloon-assisted colonoscopy (SBC)
Number of subjects: 44
Study 33720089 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral therapy with oral nucleoside analogue (entecavir or lamivudine) combined with subcutaneous peginterferon alfa-2a from week 8 for 56 weeks
Number of subjects: 59
Study 33720089 — intervention group
Group type: COMPARATOR
Intervention: Untreated observation for 80 weeks
Number of subjects: 59
Study 32171765 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrastromal injection of voriconazole
Number of subjects: 70
Study 32171765 — intervention group
Group type: COMPARATOR
Intervention: Topical therapy alone
Number of subjects: 70
Study 36315917 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab plus Trastuzumab (P + T) in ERBB2 amplification cohort
Number of subjects: 38
Study 36315917 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab plus Trastuzumab (P + T) in ERBB2/3 mutation cohort
Number of subjects: 38
Study 33727642 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid beverage lacking dopamine precursors
Number of subjects: 34
Study 33727642 — intervention group
Group type: COMPARATOR
Intervention: Balanced amino acid beverage (control)
Number of subjects: 34
Study 33727642 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine precursor depletion procedure
Number of subjects: 34